Abselion Secures £6.6M Investment Led by M Ventures to Launch Amperia

Abselion, a pioneer in automated analytical instrumentation, has raised £6.6 million in Series A financing to bring its revolutionary Amperia system to market. The innovative benchtop instrument enables scientists to quantify antibodies, AAVs, and other proteins directly from crude samples in just one minute. By delivering critical data on the spot, Amperia is set to enhance efficiency and precision in life science research and bioprocessing.

The funds will support the commercialization and further development of the Amperia system, which is powered by proprietary Redox Electrochemical Detection (RED) technology. This groundbreaking approach simplifies biologics and viral vector quantification, providing accessible, automated, and cost-effective at-line measurement for labs and process environments worldwide.

The funding round was led by M Ventures, the corporate venture capital arm of science and technology leader Merck. New investors BioProcess 360 Partners and Untitled Ventures joined existing investors, including BGF and R42. The financing also brings new expertise to Abselion’s board, with Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners joining as directors.

“We are thrilled to have the support of our investment partners as we work to empower scientists with critical real-time data at the point of need,” said Ruizhi Wang, CEO of Abselion. “Amperia’s RED technology offers unmatched speed, accuracy, and convenience, enabling confident decision-making to drive bioprocess optimization and innovation.”